ClinicalTrials.gg
RecruitingNCT07287995Updated Oct 22, 2026

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

A Phase 1/2 interventional study of ASP2998 and Pembrolizumab in Locally Advanced or Metastatic Malignant Solid Tumors, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionnone(registry's first term: Carcinoma, Non-Small-Cell Lung)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Non-Small-Cell Lung, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 22, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
428
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin, and enfortumab vedotin.

This is an early development study to collect information about ASP2998 in people with solid tumors. In this study ASP2998 will be given to humans for the first time. Early development studies are mostly about safety, but also to find the most suitable dose. Other aims are to check if ASP2998 shows signs of reducing tumor growth, to learn how the body processes ASP2998, and to check if there are changes either in the TROP2 protein or in the immune system.

The main aim of the study is to check the safety of ASP2998 when given by itself and given with the standard cancer treatments, and how well it is tolerated.

People in this study will be adults with locally advanced, unresectable or metastatic solid tumors. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. People's cancer came back or became worse after previous treatment or they couldn't receive treatment. Some people who had previously refused treatment may be able to take part. This will depend on which study treatment they receive.

People will either have cancer in the bladder lining (urothelial cancer), non-small cell lung cancer (NSCLC), gastric cancer or cancer where the food pipe joins the stomach (gastroesophageal cancer, or GEJ), or certain types of breast cancer.

People cannot take part if the cancer cells have spread to the thin tissue covering the brain and spinal cord (leptomeningeal disease), have symptoms of cancer in the brain or nervous system, or need medicines to suppress their immune system.

In this study, ASP2998 will be given to humans for the first time. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin and enfortumab vedotin. The standard cancer treatment given will depend on which cancer people have.

The study will have 2 parts.

In Part 1, different small groups of people will receive lower to higher doses of ASP2998 given by itself or together with one or more of the standard cancer treatments. Any medical problems will be recorded for each dose. This is done to find suitable doses of ASP2998 to use in Part 2.

In Part 2, other different small groups will receive suitable doses of ASP2998 worked out from Part 1. ASP2998 will either be given by itself or given together with one or more of the standard cancer treatments. This part will also check how each type of cancer responds to ASP2998 when given by itself or together with the standard cancer treatments.

In both parts of the study, safety checks will be done at each visit, and the doctors will continue to check for medical problems throughout the study. ASP2998 will be given slowly through a tube into a vein (infusion). People will continue to receive ASP2998 until their cancer gets worse, they can't tolerate ASP2998, they start other cancer treatment, they or the doctor decides the person should stop receiving ASP2998.

02

Conditions studied

  • Locally Advanced or Metastatic Malignant Solid Tumors

Browse trials for

Keywords

  • ASP2998
  • Safety
  • Tolerability
  • Pembrolizumab
  • Enfortumab Vedotin
  • Carboplatin
  • Non-small cell lung cancer
  • Gastroesophageal junction cancer
  • Breast cancer
  • Pharmacokinetics
  • Urothelial carcinoma
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the ASP2998 monotherapy dose escalation (excluding urothelial and non-small cell lung cancer (NSCLC) tumor-specific backfill participants), the following criteria apply:

    • Participant has a confirmed diagnosis of locally advanced unresectable or solid tumors.
    • Participant has progressed on, is ineligible for, or has refused all available standard therapies (no limit to the number of prior treatment regimens).
    • Prior exposure to TROP2, stimulator of interferon genes (STING) agonist or topoisomerase I (TopI) directed therapy is allowed.
    • Participant must have one of the following : Urothelial carcinoma, NSCLC (nonsquamous cell histology), Gastric/ gastroesophageal junction (GEJ) cancer, Breast cancer (human epidermal growth factor receptor 2 []-negative; local testing for HER2 status is acceptable).
    • For all tumor types, any component of neuroendocrine histology is ineligible.
  • For the ASP2998 NSCLC (2L)+ Monotherapy Dose Expansion Cohort(s) (including the tumor-specific backfill participants from the monotherapy dose escalation), the following criteria apply:

    • Participant has locally advanced unresectable or metastatic NSCLC with known programmed cell death-1 () status, without actionable oncogenic alteration (AGA), according to local testing.
    • Participant must have or cytologically confirmed diagnosis of locally advanced unresectable or metastatic NSCLC that has progressed on or after receiving platinum-based chemotherapy and/or checkpoint inhibitors according to local/regional standard of care.
    • Participant is also eligible if there is disease progression within 12 months of receiving or adjuvant therapy for resectable disease.
    • Participant must be eligible to receive treatment in 2L+ setting.
    • Participant must have had no more than 3 prior lines of therapy.
    • No prior exposure to TROP2, STING agonist or TopI directed therapy is allowed.
  • For the ASP2998 Urothelial Carcinoma Monotherapy Dose Expansion Cohort(s) (including the tumor-specific backfill participants from the monotherapy dose escalation), the following criteria apply:

    • Participant must have histologically or cytologically confirmed diagnosis of urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter or urethra) in locally advanced unresectable or metastatic setting that has progressed on a combination of enfortumab vedotin and pembrolizumab according to local/regional standard of care. Participant with urothelial carcinoma (transitional cell) with \< 50% squamous differentiation or mixed cell types is eligible.
    • Participant is also eligible if there is disease progression within 12 months of receiving adjuvant or neoadjuvant therapy for resectable disease.
    • Participant must be eligible to receive treatment in 2L+ setting.
    • Participant must have had no more than 3 prior lines of therapy.
    • No prior exposure to TROP2, STING agonist or TopI directed therapy is allowed.
  • For ASP2998 combination therapy (including the tumor-specific backfill participants from the combination therapy dose escalation), the following criteria apply for the NSCLC first line (1L) ASP2998 + Pembrolizumab + Carboplatin Dose Escalation and Expansion Cohort(s):

    • Participant has locally advanced unresectable or metastatic NSCLC (adenocarcinoma only, no mixed histology allowed), with known PD-L1 status, without AGA, according to local testing.
    • Participant is also eligible if there is disease progression > 12 months after completing adjuvant or neoadjuvant therapy for resectable disease.
    • Participant has not received prior therapy for metastatic disease.
    • No prior exposure to TROP2, STING agonist or TopI directed therapy is allowed in dose escalation or dose expansion.
  • For ASP2998 combination therapy (including the tumor-specific backfill participants from the combination therapy dose escalation), the following criteria apply for the Urothelial Carcinoma 1L ASP2998 + Pembrolizumab + Enfortumab Vedotin Dose Escalation and Expansion Cohort(s):

    • Participant must have histologically or cytologically confirmed diagnosis of urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter or urethra) in locally advanced unresectable or metastatic setting. Participant with urothelial carcinoma (transitional cell) with \< 50% squamous differentiation or mixed cell types is eligible.
    • Participant is also eligible if there is disease progression > 12 months after completing adjuvant or neoadjuvant therapy for resectable disease.
    • Participant has not received prior therapy for metastatic disease.
    • No prior exposure to TROP2, STING agonist or TopI directed therapy is allowed in dose escalation or dose expansion.
  • For ASP2998 combination therapy (including the tumor-specific backfill participants from the combination therapy dose escalation), the following criteria apply for the NSCLC 2L+ ASP2998 + Pembrolizumab Dose Escalation Cohort(s):

    • Participant has locally advanced unresectable or metastatic NSCLC with known PD-L1 status, without AGA, according to local testing.
    • Participant has progressed on or after receiving platinum-based chemotherapy and/or checkpoint inhibitors according to local/regional standard of care.
    • Participant is also eligible if there is disease progression within 12 months of receiving neoadjuvant or adjuvant therapy for resectable disease.
    • Participant may be eligible to receive treatment in 2L+ setting.
    • Participant must have had no more than 3 prior lines of therapy.
    • Prior exposure to TROP2, STING agonist or TopI directed therapy is allowed.
  • For ASP2998 combination therapy (including the tumor-specific backfill participants from the combination therapy dose escalation), the following criteria apply for the Urothelial Carcinoma 2L+ ASP2998 + Pembrolizumab Dose Escalation Cohort(s):

    • Participant must have histologically or cytologically confirmed diagnosis of urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter or urethra) in locally advanced unresectable or metastatic setting that has progressed on a combination of enfortumab vedotin and pembrolizumab according to local/regional standard of care. Participant with urothelial carcinoma (transitional cell) with \< 50% squamous differentiation or mixed cell types is eligible.
    • Participant is also eligible if there is disease progression within 12 months of receiving adjuvant or neoadjuvant therapy for resectable disease.
    • Participant must be eligible to receive treatment in 2L+ setting.
    • Participant must have had no more than 3 prior lines of therapy.
    • Prior exposure to TROP2, STING agonist or TopI directed therapy is allowed.
  • For ASP2998 combination therapy (including the tumor-specific backfill participants from the combination therapy dose escalation), the following criteria apply for the Urothelial Carcinoma 2L+ ASP2998 + Enfortumab Vedotin Dose Escalation Cohort(s):

    • Participant must have histologically or cytologically confirmed diagnosis of urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter or urethra) in locally advanced unresectable or metastatic setting that has progressed on a combination of enfortumab vedotin and pembrolizumab according to local/regional standard of care. Participant with urothelial carcinoma (transitional cell) with \< 50% squamous differentiation or mixed cell types is eligible.
    • Participant is also eligible if there is disease progression within 12 months of receiving adjuvant or neoadjuvant therapy for resectable disease.
    • Participant must be eligible to receive treatment in 2L+ setting.
    • Participant must have had no more than 3 prior lines of therapy.
    • Prior exposure to TROP2, STING agonist or TopI directed therapy is allowed.
  • Participant has a predicted ≥ 12 weeks.
  • Participant has an (ECOG) performance status of 0 or 1.
  • Participant has at least 1 per (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Participant's adverse events (AEs) (excluding alopecia) from prior anticancer therapy have improved to Grade 1 or baseline within 14 days prior to the first dose of study intervention.
  • Participant has adequate organ function as indicated by laboratory values (If a participant has received a recent blood transfusion, the laboratory tests must be obtained ≥ 14 days after any blood transfusion.)
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who has a negative serum pregnancy test and confirmed not pregnant by medical interview at screening and agrees to follow the guidance from the time of through 7 months after final study intervention administration.
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the period and for 7 months after final study intervention administration.
  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period and for 7 months after final study intervention administration.
  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 4 months after final study intervention administration.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 4 months after final study intervention administration.
  • Male participant must not donate sperm during the treatment period and for 4 months after final study intervention administration.
  • Participant agrees not to participate in another interventional study while receiving study intervention in the present study/participating in the present study (participant who is currently in the follow-up period of an interventional clinical study is allowed).

Exclusion criteria

Exclusion Criteria:

  • Participant weighs \< 40 kg during screening.
  • Participant has known active central nervous system (CNS) . NOTE: A participant with that have been treated with surgery and/or radiation therapy, who is no longer taking pharmacologic doses of and is neurologically stable, is eligible. Prophylactic use of anticonvulsants is permitted.
  • Participant has any of the following:

    • Any history of recurrent Grade 3 AEs/ immune-related AEs (irAEs) or history of Grade 4 irAEs related to prior anticancer therapy.
    • Recurrent Grade 3 or Grade 4 toxicities related to prior anticancer therapy not improved to Grade ≤ 1 or baseline per National Cancer Institute (NCI-CTCAE) v5.0 or higher at least 28 days prior to initiating screening. NOTE: Participant with chronic, stable Grade ≤ 2 toxicities is eligible if the toxicity has not worsened beyond Grade 2 for at least 3 months prior to C1D1 and is managed with standard of care treatment, and is considered by the investigator to be related to prior anticancer therapy. However, a participant who meets other exclusion criteria will be excluded from the study regardless of the above provisions.
  • Participant has active or prior or inflammatory disorders requiring systemic anti-inflammatory or therapy within the past 3 years. Participants with type 1 diabetes mellitus or endocrinopathies stably maintained on appropriate replacement therapy will not be excluded.
  • Participant has uncontrolled diabetes mellitus. For cohorts receiving enfortumab vedotin, uncontrolled diabetes is defined as (HbA1c) of ≥ 8% or HbA1c of 7% to \< 8% with associated diabetes symptoms (polyuria or polydipsia).
  • Participant has as a manifestation of the current .
  • Participant has a known additional malignancy that requires active treatment, with the exception of any of the following:

    • Locally curable malignancies that have been apparently cured with no recurrence in the past 2 years.
    • Adequately treated stage I cancer from which the participant is currently in remission and has been in remission for ≥ 2 years.
    • Any other cancer from which the participant has been disease-free for ≥ 5 years.
  • Participant has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of first administration of study intervention. Inhaled or topical steroids and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Participant has jaundice or known current active liver disease from any cause, including hepatitis A (hepatitis A virus (HAV) immunoglobulin M (IgM) positive, but testing for hepatitis A viral load in screening is not required), (hepatis B virus (HBV) (hepatitis B surface antigen positive, or HBV DNA positive if HBsAg is negative and anti-HBs and/or anti-HBc positive)), or (HCV antibody positive, confirmed by HCV RNA). NOTE: screening for these infections should be conducted per local requirements.
  • Participant has a known history of (HIV) infection with acquired immunodeficiency syndrome (AIDS)-related complications. HIV testing will be conducted per local requirements.
  • Participant has cardiac disease, defined as any of the following:

    • Clinically significant cardiac arrhythmias including bradyarrhythmia which are poorly controlled. Rate-controlled atrial fibrillation is permitted.
    • Congenital long syndrome.
    • corrected QT interval by Fridericia (QTcF) ≥ 470 msec at screening. (ECGs) will be performed in triplicate during screening; the average of the triplicate readings will be used in the calculation of QTc. If the QTc is prolonged in a participant with a pacemaker or a right sided bundle branch block, the participant may be enrolled. Participant with a left sided bundle branch block will be excluded.
    • History of clinically significant cardiac disease or congestive heart failure greater than (NYHA) Class II or (LVEF) measurement of \< 50% at baseline. Participant must not have had unstable angina (symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months.
    • Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg that has been confirmed by 2 successive measurements, despite optimal medical management.
    • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before start of study intervention.
  • Participant has a history of non-infectious interstitial lung disease (ILD)/pneumonitis, has current Grade ≥ 1 ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Participant with previously diagnosed Grade 1 radiation pneumonitis is allowed to be screened for the study. Radiation pneumonitis must be confined to the previously irradiated area of the lung and completely resolved. However, any participant with a history of radiation pneumonitis that required treatment (e.g., steroid) will be excluded, regardless of resolution.
  • Participant has inadequate pulmonary reserve due to pulmonary, heart or other disease.
  • Participant has a confirmed oxygen saturation (SpO2) \< 92% at screening.
  • Participant requires chronic oxygen supplementation therapy inclusive of noninvasive ventilation or bilevel positive airway pressure.
  • Participant has evidence of structural compromise to the trachea for any reason, including underlying malignancy.
  • Participant has had major surgery within 4 weeks prior to first dose of study intervention.
  • Participant currently has or has a history of Grade 2 or higher eye disorder, as per NCI-CTCAE v5.0 or higher.
  • Participant is at a significant risk of bleeding due to medical condition(s) or use of anticoagulants, or has a history of life-threatening bleeding (e.g., intracranial bleeding).
  • Participant has current peripheral neuropathy Grade 2 or higher (specific for enfortumab vedotin or carboplatin-containing cohorts only).
  • Participant has a history of Grade 2 or higher hearing loss (specific for the carboplatin-containing cohort only).
  • Participant has received prior TROP2 targeting agents, STING agonists or TopI inhibitor (exception: dose escalation cohorts in monotherapy and 2L+ combination therapy).
  • Participant has received prior immuno-oncology anticancer therapy within 6 weeks prior to the first dose of study intervention. Participant has received any other prior anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study intervention.
  • Participant has received prior radiation therapy within 14 days of the first dose of study intervention. Participant must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week is permitted for palliative radiation (≤ 3 weeks of radiotherapy) to non-CNS disease.
  • Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
  • Participant is expected to require another form of anticancer therapy while on study intervention.
  • Participant is receiving anticoagulants (vitamin K antagonists or direct oral anticoagulants) or antiplatelet agents. Low dose aspirin is allowed.
  • Participant has received any therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study intervention.
  • Participant has any condition that makes the participant unsuitable for study participation.
  • Participant has a known or suspected to study intervention or any components of the formulation used.
  • Participant has history of life-threatening (anaphylaxis) hypersensitivity reactions to monoclonal antibodies, bispecifics, immunomodulatory drugs or antibody-drug conjugates (ADCs).
  • Participant with severe or very severe based on Global Initiative for Obstructive Lung Disease (GOLD) criteria.
  • Participant with active hemoptysis within 4 weeks of study enrollment.
  • Participant with an airway stent.
  • Participant with endobronchial tumor or tumor involvement of the airways.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
428 participants (estimated)

Study arms

  • Experimental
    ASP2998 Dose Escalation

    Participants with urothelial carcinoma (UC), NSCLC, gastric/GEJ cancer or breast cancer (HER2-negative) will receive sequential doses of ASP2998 in a 21-day cycle.

    Drug: ASP2998

  • Experimental
    ASP2998 Dose Expansion

    Participants with UC or NSCLC will receive ASP2998 in a 21-day cycle with dose level(s) selected from dose escalation.

    Drug: ASP2998

  • Experimental
    ASP2998 Monotherapy Dose Escalation (Tumor Specific)

    Participants with select tumor types will receive ASP2998 in a 21-day cycle at dose level(s) based on emerging data.

    Drug: ASP2998

  • Experimental
    ASP2998 Monotherapy Dose Expansion (Tumor Specific)

    Participants with select tumor types will receive ASP2998 in a 21-day cycle at dose level(s) based on emerging data.

    Drug: ASP2998

  • Experimental
    ASP2998 Combination Therapy Dose Escalation (Tumor Specific)

    Participants with select tumor types will receive ASP2998 in a 21-day cycle at dose level(s) based on emerging data.

    Drug: ASP2998 · Drug: Pembrolizumab · Drug: Enfortumab Vedotin · Drug: Carboplatin

  • Experimental
    ASP2998 Combination Therapy Dose Expansion (Tumor Specific)

    Participants with select tumor types will receive ASP2998 in a 21-day cycle at dose level(s) based on emerging data.

    Drug: ASP2998 · Drug: Pembrolizumab · Drug: Enfortumab Vedotin · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    A DLT is defined as any event meeting the DLT criteria occurring within 21 days of first dose on Cycle 1 Day 1 (C1D1) that cannot clearly be attributed to a cause other than ASP2998 administered in monotherapy or in combination with standard treatments.

    Time frame: Up to 21 days

  2. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures. A TEAE is an AE with onset at any time from first dosing until last scheduled procedure.

    Time frame: Up to 21 Months

  3. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 21 months

  4. Number of participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 19 months

  5. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 19 months

  6. Number of Participants with Physical Examination (PE) abnormalities and/or AEs

    Number of participants with potentially clinically significant PE values.

    Time frame: Up to 19 months

  7. Number of Participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status score

    The ECOG scale will be used to assess performance status. Scores range from 0 (fully active) to 5 (dead). Negative change scores represent an improvement. Positive scores represent a decline in performance.

    Time frame: Up to 19 months

Secondary outcomes

  1. Objective Response Rate (ORR) of ASP2998 per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    ORR is defined as the proportion of participants whose best overall response is rated as Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator.

    Time frame: Up to 27 months

  2. Duration of Response (DOR) of ASP2998 per RECIST v1.1

    DOR is defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented progressive disease (PD) per RECIST v1.1 as assessed by the investigator or death due to any cause, whichever occurs first.

    Time frame: Up to 27 months

  3. Disease Control Rate (DCR) of ASP2998 per RECIST v1.1

    DCR is defined as the proportion of participants whose best overall response is rated as CR, PR or stable disease (SD) per RECIST v1.1 as assessed by the investigator.

    Time frame: Up to 27 months

  4. Progression Free Survival (PFS) per RECIST v1.1

    PFS is defined as the time from the first dose of study intervention until the date of documented PD per RECIST v1.1 as assessed by the investigator or until death for any cause, whichever comes first.

    Time frame: Up to 27 months

  5. Overall Survival (OS)

    OS is defined as the time from the first dose of study intervention until death due to any cause.

    Time frame: Up to 33 months

  6. Pharmacokinetics (PK) of ASP2998 in plasma: area under the concentration-time curve at 21 days (AUC21d)

    AUC21d will be recorded from the PK plasma samples collected.

    Time frame: Up to 18 months

  7. PK of ASP2998 in plasma: maximum concentration (Cmax)

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 18 months

  8. PK of ASP2998 in plasma: trough concentration (Ctrough)

    Ctrough will be recorded from the PK plasma samples collected.

    Time frame: Up to 18 months

  9. PK of ASP2998 in plasma: time of maximum concentration (tmax)

    tmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 18 months

  10. Incidence rate of trophoblast cell surface antigen 2 (TROP2) expression in tumor

    Incidence rate of TROP2 expression in tumor will be evaluated from tissue samples collected.

    Time frame: Up to 18 months

  11. Expression levels of TROP2 in tumor

    Expression levels of TROP2 expression in tumor will be evaluated from tissue samples collected.

    Time frame: Up to 18 months

  12. Change of TROP2 expression in tumor

    Change of TROP2 expression in tumor will be evaluated from tissue samples collected.

    Time frame: Up to 18 months

  13. Change in CD8 T-cell lymphocytes in paired biopsies

    Change in CD8 T-cell lymphocytes in paired biopsies will be evaluated from tissue samples collected.

    Time frame: Up to 18 months

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2029, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Feb 5, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • AdventHealth Medical Group Oncology Research Celebration · Celebration, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added
    Show site
    • AdventHealth Medical Group Oncology Research Celebration · Celebration, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287995
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Feb 5, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Astellas Pharma Global Development, Inc.
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Monitor
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion